Telmisartan
Prescription ·Exploratory record · not publication-reviewed ·Updated July 13, 2026
Telmisartan is a long-acting angiotensin II receptor blocker (ARB) used to treat hypertension and to reduce the risk of cardiovascular events in patients at high cardiovascular risk who cannot tolerate ACE inhibitors. By selectively blocking the angiotensin II type 1 (AT1) receptor, it produces vasodilation and lowers blood pressure without the cough commonly seen with ACE inhibitors. It has one of the longest half-lives in its class, which supports sustained 24-hour blood pressure control with once-daily dosing.
Exploratory record, not a reviewed medical publication.
See the editorial and medical-review policies for the publication gate.
This generated database record has not completed a claim-level review by a qualified human medical reviewer. Bibliography links and evidence labels are not approval. The page remains available for reference and is excluded from search indexing.
What the research says.
A quick, data-only summary. The full evidence, dosing, and sources are below.
Telmisartan is a long-acting angiotensin II receptor blocker (ARB) used to treat hypertension and to reduce the risk of cardiovascular events in patients at high cardiovascular risk who cannot tolerate ACE inhibitors. NutriStack rates the supporting evidence as strong. Common adult dosing is Hypertension: typically 40 mg orally once daily (range 20 mg to 80 mg once daily); start lower (20 mg or 40 mg) and titrate. Cardiovascular risk reduction: 80 mg orally once daily., though a prescriber sets the actual dose. This profile indexes 4 sources.
- Treatment of essential hypertension (alone or in combination with other antihypertensives)4
- Reduction of cardiovascular morbidity and mortality in patients at high cardiovascular risk who are intolerant of ACE inhibitors2,1
- Sustained 24-hour blood pressure control with once-daily dosing due to a long half-life4
- Renal and cardiovascular protection in conditions associated with renin-angiotensin system activation1,2
- Dizziness or lightheadedness
- Hypotension, including orthostatic hypotension (more likely in volume-depleted patients)
- Hyperkalemia (elevated blood potassium), increased risk with potassium supplements or potassium-sparing diuretics
- Known hypersensitivity to telmisartan or any component of the formulation1,2
- Pregnancy (drugs acting on the renin-angiotensin system can cause fetal injury and death; discontinue as soon as pregnancy is detected)3
The bottom line
Evidence rating strong. Most-documented uses: treatment of essential hypertension (alone or in combination with other antihypertensives), reduction of cardiovascular morbidity and mortality in patients at high cardiovascular risk who are intolerant of ace inhibitors, sustained 24-hour blood pressure control with once-daily dosing due to a long half-life. 4 sources indexed (2001–2014), with 0 interaction records on file.
How it works, mechanistically.
Core mechanism
Telmisartan selectively and competitively blocks the binding of angiotensin II to the angiotensin II type 1 (AT1) receptor in vascular smooth muscle, the adrenal cortex, and other tissues. Angiotensin II is the principal vasoactive effector of the renin-angiotensin-aldosterone system, and its actions at the AT1 receptor cause vasoconstriction, aldosterone release, sodium and water retention, sympathetic activation, and vascular and cardiac remodeling. By antagonizing this receptor, telmisartan promotes vasodilation, reduces aldosterone-driven sodium retention, and lowers systemic vascular resistance and blood pressure. Because it acts downstream of angiotensin II generation, its effect is independent of the enzymatic pathway used to form angiotensin II and it does not inhibit the breakdown of bradykinin, which explains the lower incidence of cough compared with ACE inhibitors. Reduced aldosterone activity decreases renal potassium excretion, which is the basis for its risk of hyperkalemia, particularly when combined with potassium supplements, potassium-sparing diuretics, or in renal impairment. Telmisartan is also a partial agonist of the peroxisome proliferator-activated receptor gamma (PPAR-gamma), a property that may contribute modest favorable metabolic effects, though this is not the basis of its approved use.2,1
Dosing & protocol.
Can be taken with or without food; food slightly reduces the area under the curve but the effect is not clinically significant. Bioavailability is dose-dependent (roughly 42 to 58 percent). Take at the same time each day for consistent 24-hour blood pressure control. Do not remove a tablet from its blister until immediately before dosing because the tablets are hygroscopic.3
Full safety detail.
Side effects
- Dizziness or lightheadedness
- Hypotension, including orthostatic hypotension (more likely in volume-depleted patients)
- Hyperkalemia (elevated blood potassium), increased risk with potassium supplements or potassium-sparing diuretics
- Increased blood urea nitrogen and serum creatinine, especially in renal artery stenosis or volume depletion
- Upper respiratory tract symptoms and sinus congestion
- Back pain and myalgia
- Diarrhea or dyspepsia
- Fatigue
- Angioedema (rare)
- Acute kidney injury in susceptible patients (volume depletion, bilateral renal artery stenosis, concomitant NSAIDs)
Contraindications
- Known hypersensitivity to telmisartan or any component of the formulation1,2
- Pregnancy (drugs acting on the renin-angiotensin system can cause fetal injury and death; discontinue as soon as pregnancy is detected)3
- Concomitant use with aliskiren in patients with diabetes mellitus1
- Biliary obstructive disorders (caution; telmisartan is eliminated primarily via bile)
- Severe hepatic impairment (use not recommended)3
Sources, by evidence tier.
Numbered references. Citations throughout the page link here.
Randomized controlled trials
2- 1Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events (ONTARGET)Yusuf S, Teo KK, Pogue J, et al. (ONTARGET Investigators) · New England Journal of Medicine · 2008
In patients with vascular disease or high-risk diabetes, telmisartan was noninferior to ramipril for the composite of cardiovascular death, myocardial infarction, stroke, or hospitalization for heart failure, with less cough and angioedema; combining the two agents increased adverse events such as hyperkalemia and renal dysfunction without additional benefit.
- 2Effects of the Angiotensin-Receptor Blocker Telmisartan on Cardiovascular Events in High-Risk Patients Intolerant to ACE Inhibitors (TRANSCEND)Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators · Lancet · 2008
In ACE-inhibitor-intolerant patients, telmisartan modestly reduced a composite of cardiovascular death, myocardial infarction, and stroke compared with placebo and was well tolerated.
Reviews & position papers
2- 3Drug-induced hyperkalemiaBen Salem C, Badreddine A, Fathallah N, et al. · Drug Safety · 2014
Agents that suppress the renin-angiotensin-aldosterone system, including angiotensin receptor blockers, reduce renal potassium excretion and can cause clinically significant hyperkalemia, with risk amplified by concurrent potassium supplementation, potassium-sparing diuretics, NSAIDs, and impaired kidney function.
- 4Telmisartan: a review of its pharmacological properties and therapeutic use in the management of hypertensionSharpe M, Jarvis B, Goa KL · Drugs · 2001
Telmisartan's long terminal half-life of about 24 hours supports effective and sustained reduction of systolic and diastolic blood pressure across the full dosing interval, including the early morning period, with once-daily administration.
Common questions.
Quick answers about Telmisartan, drawn from the data on this page.
What is Telmisartan?
Telmisartan is a long-acting angiotensin II receptor blocker (ARB) used to treat hypertension and to reduce the risk of cardiovascular events in patients at high cardiovascular risk who cannot tolerate ACE inhibitors. By selectively blocking the angiotensin II type 1 (AT1) receptor, it produces vasodilation and lowers blood pressure without the cough commonly seen with ACE inhibitors. It has one of the longest half-lives in its class, which supports sustained 24-hour blood pressure control with once-daily dosing.
What is Telmisartan used for?
Commonly cited benefits of Telmisartan include: Treatment of essential hypertension (alone or in combination with other antihypertensives); Reduction of cardiovascular morbidity and mortality in patients at high cardiovascular risk who are intolerant of ACE inhibitors; Sustained 24-hour blood pressure control with once-daily dosing due to a long half-life; Renal and cardiovascular protection in conditions associated with renin-angiotensin system activation. NutriStack rates the overall evidence as strong.
What is a typical dose of Telmisartan?
A typical adult dose of Telmisartan is Hypertension: typically 40 mg orally once daily (range 20 mg to 80 mg once daily); start lower (20 mg or 40 mg) and titrate. Cardiovascular risk reduction: 80 mg orally once daily.. The commonly recommended form is Oral tablet (20 mg, 40 mg, 80 mg); also available in fixed-dose combinations with hydrochlorothiazide or amlodipine. These are general ranges, not personalized advice; confirm the right dose with a clinician.
What are the side effects of Telmisartan?
Reported side effects include dizziness or lightheadedness, hypotension, including orthostatic hypotension (more likely in volume-depleted patients), hyperkalemia (elevated blood potassium), increased risk with potassium supplements or potassium-sparing diuretics, increased blood urea nitrogen and serum creatinine, especially in renal artery stenosis or volume depletion, upper respiratory tract symptoms and sinus congestion, back pain and myalgia. This is educational information; check with a healthcare professional before use.
How strong is the evidence for Telmisartan?
NutriStack rates this as Strong, meaning multiple high-quality meta-analyses or systematic reviews converge on the same finding. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.
Use this with your stack
Telmisartan in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.